<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884348</url>
  </required_header>
  <id_info>
    <org_study_id>Kangdong2017-03-005</org_study_id>
    <nct_id>NCT03884348</nct_id>
  </id_info>
  <brief_title>Tailored H. Pylori Eradication Based on Clarithromycin Resistance</brief_title>
  <official_title>Helicobacter Pylori Eradication According to Sequencing-based 23S Ribosomal RNA Point Mutation Associated With Clarithromycin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangdong Sacred Heart Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigated the point mutations in the 23S rRNA genes of patients infected
      with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on
      the identified clinically significant point mutations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sequencing-based detection of point mutations identified four mutations that were considered
      clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were
      considered clinically insignificant.

      Participants who did not have point mutations related to clarithromycin resistance and/or had
      clinically insignificant point mutations were treated with PAC (proton pump inhibitor,
      amoxicillin, clarithromycin) for 7 days, while participants with clinically significant point
      mutations were treated with PAM (proton pump inhibitor, amoxicillin, metronidazole) for 7
      days. H. pylori eradication rates were compared between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori eradication rate</measure>
    <time_frame>2 year</time_frame>
    <description>Number of participant with successful Helicobacter pylori eradication</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">431</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Antibiotic Resistant Strain</condition>
  <arm_group>
    <arm_group_label>PAM-treated clarithromycin-resistance group</arm_group_label>
    <description>Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC-treated nonresistance group</arm_group_label>
    <description>Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>proton pump inhibitor, amoxicillin, clarithromycin</intervention_name>
    <description>non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin</description>
    <arm_group_label>PAC-treated nonresistance group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>proton pump inhibitor, amoxicillin, metronidazole</intervention_name>
    <description>clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole</description>
    <arm_group_label>PAM-treated clarithromycin-resistance group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Helicobacter-pylori positive patients with gastritis, ulcer, adenoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Helicobacter pylori infection

        Exclusion Criteria:

          -  H. pylori eradication therapy within 1 year,

          -  antibiotics within 4 weeks,

          -  surgery for gastric cancer

          -  malignant tumors other than gastric cancer

          -  end-stage renal disease

          -  liver cirrhosis,

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woon Geon Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangdong Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Shin, Woon Geon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

